Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma 2Adenocarcinoma 2Sexual Dysfunction, Physiological 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Mouth Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Erectile Dysfunction 1Astrocytoma 1Abdominal Cancer 1

Interventions

pembrolizumab 1Tadalafil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pyridoxine-dependent epilepsy × Tadalafil × Clear all
NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

Phase 2 Completed
7 enrolled 14 charts
GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡